When John Flannery was chosen to head GE Healthcare in 2014, his background as chief dealmaker for the industrial conglomerate led to speculation GE might consider spinning off its somewhat sickly health business.
In fact, he has nursed it back to improving sales and profits by focusing primarily on organic growth opportunities, and the business remains core to GE.
Flannery will take over General Electric Co from Jeff Immelt, who is stepping aside after 16 years as head of the conglomerate he helped steer through the financial crisis but which is now worth a third less than when he took over.
On Flannery’s watch, the healthcare unit – best-known for imaging and diagnostics – has also expanded into life sciences, offering a range of services to pharmaceutical and biotech companies.
GE faces tough competition for its medical imaging machines, which include MRI scanners and ultrasound devices, from rivals including Philips and Siemens, as well as younger Asian upstarts.
But a focus on expansion into new markets has helped lift sales at GE Healthcare to $18.3 billion last year, with organic revenue increasing by 5 percent and margins by 100 basis points.
Flannery has worked hard to move GE into newer areas of healthcare like life sciences, where GE has emerged as a significant player in helping with the production of biological drugs and cell therapies.
Such drugs, given by injection or infusion, are a pivotal driver of innovation in the drugs industry, being used to treat complex diseases from rheumatoid arthritis to cancer.
Flannery told Reuters last year he aimed to “double down on life sciences”, given this business’s large and high-margin opportunities.
One of the more innovative ideas launched by GE recently is the design of prefabricated drug factories for making complex biotech medicines, an idea it is pioneering in both China and Ireland.
GE reckons its “off-the-shelf” modular factories are 25 to 50 percent cheaper than the traditional plants and can be constructed in just 18 months rather than the typical three years.
Some analysts continue to question whether healthcare truly fits with mainstay GE industries like power generation and jet engines, but Flannery’s elevation suggests the group is not contemplating ditching healthcare any time soon.
In a sign of continuity, GE said Kieran Murphy, who currently heads life sciences, would lead the wider GE Healthcare division – and the company stated bluntly: “Healthcare is a key GE business now and in the future.”
By Ben Hirschler
Airnov provides critical healthcare industries with high-quality, controlled atmosphere packaging, to protect their products from moisture and oxygen. The business has manufacturing facilities in the USA, France, China and India and employs around 700 people.
Takeda of Japan has partnered with Hong Kong-based Hutchmed, gaining the commercial rights to colorectal cancer drug fruquintinib outside of China for $400 million up front, plus $730 million in potential milestone payments. Takeda also will help develop fruquintinib, which can be applied to subtypes of refractory metastatic colorectal cancer, regardless of biomarker status, the companies said.
On April 3, Scangos, who’s been chief executive officer at Vir since the start of 2017, will hand over the reins to Marianne De Backer, Ph.D. De Backer comes over from Bayer, where she currently heads up pharmaceutical strategy, business development and licensing. Alongside her CEO appointment, De Backer is set to join Vir’s board of directors, the company said Wednesday.